Cohort 1: Confirmed diagnosis of TP53wt DLBCL (WHO); R/R DLBCL after at least 2 prior lines of treatment or 1 prior for patients who are ineligible for stem cell transplant
Cohort 2: Confirmed diagnosis of TP53wt CLL (iwCLL); R/R CLL after at least 1 prior line of treatment
ECOG 0 to 2
Adequate hematologic, hepatic, and renal functions.
You may not be if
Prior treatment with any MDM2 inhibitor
Prior treatment with any BTK inhibitor
Clareo Health | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
